Regulation of Brain Glucose Metabolism in Type 1 Diabetes

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

June 30, 2026

Conditions
Diabetes Mellitus, Type 1Hypoglycemia Unawareness
Interventions
DRUG

Dichloroacetate

Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.

Trial Locations (1)

06510

RECRUITING

Yale-New Haven Hospital, New Haven

All Listed Sponsors
lead

Yale University

OTHER